Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.1M | $24.1M | $8.5M | $3.2M | $8.2M | $7.1M | $8.6M |
| Cost of revenue | $1.1M | $6.7M | $16.2M | $20.7M | $5.2M | $11.1M | $10.9M | $13.2M |
| Gross profit | $450.0K | $384.0K | $7.9M | −$12.2M | −$2.0M | −$2.9M | −$3.8M | −$4.6M |
| Gross margin | 29.6% | 5.4% | 32.9% | -143.0% | -62.7% | -34.8% | -53.4% | -53.4% |
| R&D | $29.3M | $22.0M | $21.8M | $22.5M | $16.6M | $19.3M | $28.9M | $37.0M |
| Operating income | −$123.6M | −$61.9M | −$49.2M | −$154.6M | −$60.4M | −$64.6M | −$75.7M | −$79.5M |
| EBITDA | −$114.6M | −$135.3M | −$47.7M | −$141.3M | −$47.1M | −$47.8M | −$64.3M | −$74.4M |
| Net income | −$120.0M | −$144.8M | −$61.8M | −$154.2M | −$59.3M | −$62.5M | −$75.6M | −$78.4M |
| Net margin | -7898.6% | -2036.2% | -256.3% | -1807.5% | -1868.1% | -758.8% | -1066.2% | -914.5% |
| EPS (diluted) | -13.91 | -12.61 | -3.90 | -8.69 | -0.85 | -0.28 | -0.32 | -0.31 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $51M | $-0.08 | $-0.08–$-0.08 | 1 |
| 2027 | $106M | $0.03 | $0.03–$0.03 | 1 |
| 2028 | $155M | $0.12 | $0.12–$0.12 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ASXC.
No tracked institution reports a position in ASXC as of their last filing.
| Execution date | Ratio |
|---|---|
| 2019-12-12 | 1-for-13reverse |
No one on the platform has traded ASXC yet.
| $145M |
| — |
| JNCEJounce Therapeutics, Inc. | $1.88 | +0.00% | $99M | — |
| MIROMiromatrix Medical Inc. | $3.39 | +0.59% | $93M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 11.6× sales vs its 17.9× historical median P/S.
Fair value ≈ $0.53 · price $0.35 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ASXC What happened to the 🤡who worked in this company and ran it to ground..Hope they got Fired by Dr Sch....or whoever bought it. Remember , 🤡s, u never get into WS. ..
View on StockTwits ↗$ASXC I know nothing I tell yea. Nothing! CYDY Long strong and extremely
View on StockTwits ↗$ASXC Still can’t believe the cult group that used to pump this like it is the next $ISRG and attacked everyone who said otherwise. Between this and $AMC I have learnt a lot about the market and stupid humans in general.
View on StockTwits ↗$ALB Last time a saw a wedge the size of $ALB was $ASXC mega years ago.. it pushed 60% 🙏 well c
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.